Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q4 EPS of ($1.92), $1.31 worse than the analyst estimate of ($0.61). Revenue for the quarter came in at $240.73 million.

For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.